GSK acquires anti-thrombotic agents from Sanofi-Aventis

Published: 2004-09-09 06:58:00

Updated: 2004-09-09 06:58:00

GSK announced on September 7 the successful acquisition, on a worldwide basis, of the injectable anti-thrombotic agents Fraxiparine, Fraxodi and Arixtra and related assets including a manufacturing facility located in Notre-Dame de Bondeville, France from Sanofi-Aventis. As a part of this transac...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK